Adamas Announces Data Presentations at the 71st American Academy of Neurology Annual Meeting
May 06, 2019 21:39 ET
|
Adamas Pharmaceuticals, Inc.
EMERYVILLE, Calif., May 06, 2019 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS), a fully-integrated pharmaceutical company pioneering time-dependent medicines for central nervous...
Adamas Presents Final Results from the Two-Year, Phase 3 Open-Label Study of GOCOVRI™ in Parkinson’s Disease Patients with Dyskinesia
October 08, 2018 08:30 ET
|
Adamas Pharmaceuticals, Inc.
GOCOVRI was generally well tolerated and the safety profile was consistent with previously reported data for up to two yearsResults show a comparable 35% reduction from baseline in dyskinesia and OFF...
Adamas Announces Publication of ADS-5102 Phase 2 Clinical Trial Results in Multiple Sclerosis Journal
February 01, 2018 16:05 ET
|
Adamas Pharmaceuticals, Inc.
EMERYVILLE, Calif., Feb. 01, 2018 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq:ADMS) today announced that results of its Phase 2 proof-of-concept clinical trial of ADS-5102 (amantadine)...
Adamas Announces Publication of ADS-5102 Phase 3 EASE LID Clinical Trial in JAMA Neurology
June 12, 2017 16:01 ET
|
Adamas Pharmaceuticals, Inc.
--Placebo-Controlled Phase 3 Trial Demonstrated that ADS-5102 Significantly Reduced Both Dyskinesia and OFF Time at Six Months in Parkinson’s Disease Patients with Levodopa-induced Dyskinesia -- --...